{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:56:14Z","timestamp":1790196974197,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013392","name":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux","doi-asserted-by":"publisher","award":["Fonds d\u2019acc\u00e9l\u00e9ration des collaborations en sant\u00e9 (FACS)"],"award-info":[{"award-number":["Fonds d\u2019acc\u00e9l\u00e9ration des collaborations en sant\u00e9 (FACS)"]}],"id":[{"id":"10.13039\/100013392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Misfolded superoxide dismutase-1 (mSOD1) is an abnormal protein observed in amyotrophic lateral sclerosis (ALS) and constitutes a therapeutic target. The present study evaluated the biodistribution, dosimetry, and safety of a new antibody-based radiopharmaceutical, [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-AP-101, targeting mSOD1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Seven control participants and one patient with ALS received 41\u2009\u00b1\u20093 MBq of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-AP-101. They were followed up with five whole-body positron emission tomography (PET) scans over 10 days. Semi-automatic segmentation was performed on the images to derive time-activity curves, radiotracer effective half-life and dose exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total elimination of the radiotracer (urinary and hepatobiliary) was 25\u201330% after three days and reached a plateau after a week. At 2\u00a0h post-injection, ~\u200960% of the radiopharmaceutical remained in the blood pool, with a biological half-life of 53\u00a0h. The liver was the dose-limiting organ with 0.84 mSv\/MBq in males, 1.07 mSv\/MBq in females, and 1.23 mSv\/MBq in the female ALS patient. The spleen, adrenal glands, kidney, and heart wall were the other most irradiated organs. Average effective doses were 0.21 mSv\/MBq for males, 0.28 mSv\/MBq for females, and 0.31 mSv\/MBq for the female ALS patient. Tracer uptake in the spinal cord and vertebrae of the ALS patient, on Days 7 and 10, was more than one standard deviation higher than for the control female participants. No serious adverse event was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The single dose of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-AP-101 was safe for all participants. It provided good image quality for the biodistribution and dosimetry analysis over 10 days. Further studies are needed to demonstrate the efficacy of ALS diagnosis through PET imaging. https:\/\/www.clinicaltrials.gov\/study\/NCT05974579.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07853-y","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:27:30Z","timestamp":1774308450000},"page":"4639-4651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase I study to evaluate the dosimetry and safety of [89Zr]Zr-DFO-AP-101, a new antibody-based radiopharmaceutical to detect misfolded SOD1 in amyotrophic lateral sclerosis"],"prefix":"10.1007","volume":"53","author":[{"given":"Etienne","family":"Croteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Espinosa-Betancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Ait-Mohand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9milie","family":"Lareau-Trudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"C\u00f4t\u00e9-Bigras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Salzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"T\u00e9tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pier","family":"Houde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-4512","authenticated-orcid":false,"given":"Brigitte","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"1\u20132","key":"7853_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/21678421.2022.2059380","volume":"24","author":"P Mehta","year":"2023","unstructured":"Mehta P, Raymond J, Punjani R, Han M, Larson T, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph Lateral Scler Frontotemporal Degeneration. 2023;24(1\u20132):108\u201316. https:\/\/doi.org\/10.1080\/21678421.2022.2059380.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degeneration"},{"issue":"1","key":"7853_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/ije\/dyw061","volume":"46","author":"B Marin","year":"2017","unstructured":"Marin B, Boum\u00e9diene F, Logroscino G, Couratier P, Babron M-C, Leutenegger AL, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46(1):57\u201374. https:\/\/doi.org\/10.1093\/ije\/dyw061.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"7853_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000366191","volume":"6","author":"F Tateno","year":"2014","unstructured":"Tateno F, Sakakibara R, Kawashima K, Kishi M, Tsuyusaki Y, Aiba Y, et al. Amyotrophic lateral sclerosis presenting respiratory failure as the sole initial manifestation. Case Rep Neurol. 2014;6(2):213\u20136. https:\/\/doi.org\/10.1159\/000366191.","journal-title":"Case Rep Neurol"},{"issue":"1","key":"7853_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13311-016-0503-x","volume":"14","author":"LT Vu","year":"2017","unstructured":"Vu LT, Bowser R. Fluid-based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14(1):119\u2013. https:\/\/doi.org\/10.1007\/s13311-016-0503-x.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"7853_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4161\/pri.27602","volume":"8","author":"LI Grad","year":"2014","unstructured":"Grad LI, Cashman NR. Prion-like activity of Cu\/Zn superoxide dismutase: implications for amyotrophic lateral sclerosis. Prion. 2014;8(1):33\u201341. https:\/\/doi.org\/10.4161\/pri.27602.","journal-title":"Prion"},{"key":"7853_CR6","doi-asserted-by":"publisher","unstructured":"Bosco A, Landers DE. J. Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders). 2010;9(6):779\u201390. https:\/\/doi.org\/10.2174\/187152710793237494","DOI":"10.2174\/187152710793237494"},{"issue":"5","key":"7853_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00401-011-0805-3","volume":"121","author":"K Forsberg","year":"2011","unstructured":"Forsberg K, Andersen PM, Marklund SL, Br\u00e4nnstr\u00f6m T. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2011;121(5):623\u201334. https:\/\/doi.org\/10.1007\/s00401-011-0805-3.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"7853_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/hmg\/dds399","volume":"22","author":"KS Graffmo","year":"2013","unstructured":"Graffmo KS, Forsberg K, Bergh J, Birve A, Zetterstr\u00f6m P, Andersen PM, et al. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22(1):51\u201360. https:\/\/doi.org\/10.1093\/hmg\/dds399.","journal-title":"Hum Mol Genet"},{"issue":"7","key":"7853_CR9","doi-asserted-by":"publisher","first-page":"e11552","DOI":"10.1371\/journal.pone.0011552","volume":"5","author":"K Forsberg","year":"2010","unstructured":"Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, et al. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS ONE. 2010;5(7):e11552. https:\/\/doi.org\/10.1371\/journal.pone.0011552.","journal-title":"PLoS ONE"},{"issue":"1","key":"7853_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13024-019-0341-5","volume":"14","author":"E Tokuda","year":"2019","unstructured":"Tokuda E, Takei Y-i, Ohara S, Fujiwara N, Hozumi I, Furukawa Y. Wild-type Cu\/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis. Mol neurodegeneration. 2019;14(1):42. https:\/\/doi.org\/10.1186\/s13024-019-0341-5.","journal-title":"Mol neurodegeneration"},{"issue":"1","key":"7853_CR11","doi-asserted-by":"publisher","first-page":"14223","DOI":"10.1038\/s41598-018-31773-z","volume":"8","author":"B Par\u00e9","year":"2018","unstructured":"Par\u00e9 B, Lehmann M, Beaudin M, Nordstr\u00f6m U, Saikali S, Julien J-P, et al. Misfolded SOD1 pathology in sporadic amyotrophic lateral sclerosis. Sci Rep. 2018;8(1):14223. https:\/\/doi.org\/10.1038\/s41598-018-31773-z.","journal-title":"Sci Rep"},{"issue":"1","key":"7853_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-015-1514-0","volume":"131","author":"JI Ayers","year":"2016","unstructured":"Ayers JI, Fromholt SE, O\u2019Neal VM, Diamond JH, Borchelt DR. Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. Acta Neuropathol. 2016;131(1):103\u201314. https:\/\/doi.org\/10.1007\/s00401-015-1514-0.","journal-title":"Acta Neuropathol"},{"issue":"470","key":"7853_CR13","doi-asserted-by":"publisher","first-page":"eaah3924","DOI":"10.1126\/scitranslmed.aah3924","volume":"10","author":"M Maier","year":"2018","unstructured":"Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci Transl Med. 2018;10(470):eaah3924. https:\/\/doi.org\/10.1126\/scitranslmed.aah3924.","journal-title":"Sci Transl Med"},{"issue":"5","key":"7853_CR14","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/ene.15738","volume":"30","author":"P Corcia","year":"2023","unstructured":"Corcia P, Lunetta C, Vourc\u2019h P, Pradat PF, Blasco H. Time for optimism in amyotrophic lateral sclerosis. Eur J Neurol. 2023;30(5):1459\u201364. https:\/\/doi.org\/10.1111\/ene.15738.","journal-title":"Eur J Neurol"},{"key":"7853_CR15","doi-asserted-by":"publisher","first-page":"5864391","DOI":"10.1155\/2023\/5864391","volume":"2023","author":"AM Jamali","year":"2023","unstructured":"Jamali AM, Kethamreddy M, Burkett BJ, Port JD, Pandey MK. PET and SPECT imaging of ALS: an educational review. Mol Imaging. 2023;2023:5864391. https:\/\/doi.org\/10.1155\/2023\/5864391.","journal-title":"Mol Imaging"},{"issue":"1","key":"7853_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2967\/jnumed.124.268343","volume":"66","author":"JA Rousseau","year":"2025","unstructured":"Rousseau JA, Maier M, Ait-Mohand S, Dumulon-Perreault V, Sarrhini O, Tremblay S, et al. Antibody-Based PET Imaging of Misfolded Superoxide Dismutase 1 in an Amyotrophic Lateral Sclerosis Mouse Model. J Nucl Med. 2025;66(1):130\u20135. https:\/\/doi.org\/10.2967\/jnumed.124.268343.","journal-title":"J Nucl Med"},{"issue":"11","key":"7853_CR17","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood\u2013brain barrier. J Cereb blood flow metabolism. 2012;32(11):1959\u201372.","journal-title":"J Cereb blood flow metabolism"},{"issue":"1","key":"7853_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/0003-2697(84)90517-7","volume":"142","author":"CF Meares","year":"1984","unstructured":"Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984;142(1):68\u201378.","journal-title":"Anal Biochem"},{"key":"7853_CR19","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.21769\/BioProtoc.44","volume":"1","author":"HeF","year":"2011","unstructured":"He F. BCA (bicinchoninic acid) protein assay. Bio-protocol. 2011;1:e44. https:\/\/doi.org\/10.21769\/BioProtoc.44","journal-title":"Bio-protocol"},{"issue":"5","key":"7853_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph lateral Scler other motor neuron disorders. 2000;1(5):293\u20139. https:\/\/doi.org\/10.1080\/146608200300079536.","journal-title":"Amyotroph lateral Scler other motor neuron disorders"},{"issue":"8","key":"7853_CR21","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1021\/bc3002437","volume":"23","author":"P Fournier","year":"2012","unstructured":"Fournier P, Dumulon-Perreault V, Ait-Mohand S, Tremblay S, Benard F, Lecomte R, et al. Novel radiolabeled peptides for breast and prostate tumor PET imaging: 64Cu\/and 68Ga\/NOTA-PEG-[D-Tyr6, \u03b2Ala11, Thi13, Nle14] BBN (6\u201314). Bioconjug Chem. 2012;23(8):1687\u201393.","journal-title":"Bioconjug Chem"},{"issue":"5","key":"7853_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood.V33.5.649.649","volume":"33","author":"JA Retzlaff","year":"1969","unstructured":"Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood. 1969;33(5):649\u201367. https:\/\/doi.org\/10.1182\/blood.V33.5.649.649.","journal-title":"Blood"},{"key":"7853_CR23","doi-asserted-by":"publisher","first-page":"117054","DOI":"10.1016\/j.jns.2020.117054","volume":"417","author":"D Richards","year":"2020","unstructured":"Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. 2020;417:117054.","journal-title":"J Neurol Sci"},{"issue":"1","key":"7853_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-024-02752-8","volume":"147","author":"JK Mielke","year":"2024","unstructured":"Mielke JK, Klingeborn M, Schultz EP, Markham EL, Reese ED, Alam P, et al. Seeding activity of human superoxide dismutase 1 aggregates in familial and sporadic amyotrophic lateral sclerosis postmortem neural tissues by real-time quaking-induced conversion. Acta Neuropathol. 2024;147(1):1\u201316.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"7853_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.121.261926","volume":"63","author":"A-LN Niemeijer","year":"2022","unstructured":"Niemeijer A-LN, Oprea-Lager DE, Huisman MC, Hoekstra OS, Boellaard R, Bahce I, et al. Study of 89Zr-pembrolizumab PET\/CT in patients with advanced-stage non\u2013small cell lung cancer. J Nucl Med. 2022;63(3):362\u20137. https:\/\/doi.org\/10.2967\/jnumed.121.261926.","journal-title":"J Nucl Med"},{"issue":"6","key":"7853_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","volume":"18","author":"R Laforest","year":"2016","unstructured":"Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, et al. [89Zr] trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer. Mol imaging biology. 2016;18(6):952\u20139. https:\/\/doi.org\/10.1007\/s11307-016-0951-z.","journal-title":"Mol imaging biology"},{"issue":"8","key":"7853_CR27","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3390\/molecules26082201","volume":"26","author":"V Liberini","year":"2021","unstructured":"Liberini V, Laudicella R, Capozza M, Huellner MW, Burger IA, Baldari S, et al. The future of cancer diagnosis, treatment and surveillance: a systemic review on immunotherapy and immuno-pet radiotracers. Molecules. 2021;26(8):2201. https:\/\/doi.org\/10.3390\/molecules26082201.","journal-title":"Molecules"},{"key":"7853_CR28","doi-asserted-by":"publisher","first-page":"1026083","DOI":"10.3389\/fmed.2022.1026083","volume":"9","author":"A Lugat","year":"2022","unstructured":"Lugat A, Bailly C, Ch\u00e9rel M, Rousseau C, Kraeber-Bod\u00e9r\u00e9 F, Bodet-Milin C, et al. Immuno-PET: Design options and clinical proof-of-concept. Front Med. 2022;9:1026083. https:\/\/doi.org\/10.3389\/fmed.2022.1026083.","journal-title":"Front Med"},{"issue":"1","key":"7853_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/jpm14010040","volume":"14","author":"F Dondi","year":"2023","unstructured":"Dondi F, Pisani AR, Lucarelli NM, Gazzilli M, Talin A, Albano D, et al. Correlation between kidney uptake at [18F] FDG PET\/CT and renal function. J Personalized Med. 2023;14(1):40.","journal-title":"J Personalized Med"},{"issue":"8","key":"7853_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/MNM.0000000000000513","volume":"37","author":"SR Akers","year":"2016","unstructured":"Akers SR, Werner TJ, Rubello D, Alavi A, Cheng G. 18F-FDG uptake and clearance in patients with compromised renal function. Nucl Med Commun. 2016;37(8):825\u201332.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"7853_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5603\/NMR.a2022.0021","volume":"25","author":"Y Otomi","year":"2022","unstructured":"Otomi Y, Arai Y, Otomo M, Irahara S, Terazawa K, Kubo M, et al. Increased physiological [18F] FDG uptake in the liver and blood pool among patients with impaired renal function. Nuclear Med Rev. 2022;25(2):95\u2013100.","journal-title":"Nuclear Med Rev"},{"issue":"2","key":"7853_CR32","first-page":"204","volume":"5","author":"A Toriihara","year":"2015","unstructured":"Toriihara A, Kitazume Y, Nishida H, Kubota K, Nakadate M, Tateishi U. Comparison of FDG-PET\/CT images between chronic renal failure patients on hemodialysis and controls. Am J Nucl Med Mol Imaging. 2015;5(2):204.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"7853_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12017-012-8204-z","volume":"15","author":"P Zetterstr\u00f6m","year":"2013","unstructured":"Zetterstr\u00f6m P, Graffmo KS, Andersen PM, Br\u00e4nnstr\u00f6m T, Marklund SL. Composition of soluble misfolded superoxide dismutase-1 in murine models of amyotrophic lateral sclerosis. Neuromol Med. 2013;15(1):147\u201358.","journal-title":"Neuromol Med"},{"issue":"35","key":"7853_CR34","doi-asserted-by":"publisher","first-page":"14157","DOI":"10.1073\/pnas.0700477104","volume":"104","author":"P Zetterstr\u00f6m","year":"2007","unstructured":"Zetterstr\u00f6m P, Stewart HG, Bergemalm D, Jonsson PA, Graffmo KS, Andersen PM, et al. Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models. Proc Natl Acad Sci. 2007;104(35):14157\u201362.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"7853_CR35","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/01.jnen.0000248545.36046.3c","volume":"65","author":"PA Jonsson","year":"2006","unstructured":"Jonsson PA, Graffmo KS, Br\u00e4nnstr\u00f6m T, Nilsson P, Andersen PM, Marklund SL. Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1. J Neuropathology Experimental Neurol. 2006;65(12):1126\u201336.","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"5","key":"7853_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ana.21356","volume":"63","author":"PA Jonsson","year":"2008","unstructured":"Jonsson PA, Bergemalm D, Andersen PM, Gredal O, Br\u00e4nnstr\u00f6m T, Marklund SL. Inclusions of amyotrophic lateral sclerosis\u2013linked superoxide dismutase in ventral horns, liver, and kidney. Ann Neurol. 2008;63(5):671\u20135.","journal-title":"Ann Neurol"},{"issue":"11","key":"7853_CR37","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00259-014-2830-7","volume":"41","author":"N Pandit-Taskar","year":"2014","unstructured":"Pandit-Taskar N, O\u2019Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(11):2093\u2013105. https:\/\/doi.org\/10.1007\/s00259-014-2830-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl 6","key":"7853_CR38","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1289\/ehp.97105s61403","volume":"105","author":"MG Stabin","year":"1997","unstructured":"Stabin MG. Health concerns related to radiation exposure of the female nuclear medicine patient. Environ Health Perspect. 1997;105(suppl 6):1403\u20139. https:\/\/doi.org\/10.1289\/ehp.97105s61403.","journal-title":"Environ Health Perspect"},{"issue":"1","key":"7853_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13550-022-00884-0","volume":"12","author":"AH Dias","year":"2022","unstructured":"Dias AH, Hansen AK, Munk OL, Gormsen LC. Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients. EJNMMI Res. 2022;12(1):15.","journal-title":"EJNMMI Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07853-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07853-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07853-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:43:47Z","timestamp":1781642627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07853-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7853"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07853-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Centre int\u00e9gr\u00e9 universitaire de sant\u00e9 et services sociaux de l\u2019Estrie - Centre hospitalier universitaire de Sherbrooke (number 2024\u20135148). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}